TXA707 is an FtsZ-targeting antibacterial agent with oral bioavailability. TXA707 alters FtsZ polymerization dynamics, stabilizes nonfunctional FtsZ polymeric structures, and disrupts FtsZ Z-ring formation at midcell. TXA707 disrupts bacterial septum formation, induces cell enlargement, causes penicillin-binding protein mislocalization, and triggers cell lysis in Staphylococcus aureus cells. TXA707 acts synergistically with beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. TXA707 exerts activity against antibiotic-resistant Staphylococcus aureus isolates, including those resistant to Vancomycin (HY-B0671), Daptomycin (HY-B0108), and Linezolid (HY-10394). TXA707 functions as the active metabolite of prodrug TXA-709, exhibits linear pharmacokinetics after oral TXA-709 administration in neutropenic mice, and links antibacterial efficacy to AUC/MIC pharmacodynamic index. TXA707 shows minimal toxicity to mammalian cells. TXA707 can be used for the research of methicillin-resistant Staphylococcus aureus infections, methicillin-sensitive Staphylococcus aureus infections, vancomycin-intermediate Staphylococcus aureus infections, vancomycin-resistant Staphylococcus aureus infections, daptomycin-nonsusceptible Staphylococcus aureus infections, and linezolid-nonsusceptible Staphylococcus aureus infections[1][2][3].
Molecular Weight:
389.30
Purity:
99.92
CAS Number:
[1609670-89-4]
Formula:
C15H8F5N3O2S
Target:
Bacterial
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
